BioCentury | Apr 17, 2018
Preclinical News

New protein complex sensitizes cancers to PARP inhibitors

Researchers at University of Copenhagen and colleagues used a network-based proteomics approach to identify shieldin, a protein complex that sensitizes BRCA1-deficient cancers to PARP inhibitors, suggesting that shieldin component levels could guide precision medicine strategies....
Items per page:
1 - 1 of 1